A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Birmingham scientists have shown that a sequence of just three amino acids may reduce the severity of psoriasis, when applied ...

Birmingham scientists have shown that a sequence of just three amino acids may reduce the severity of psoriasis when applied ...

Psoriasis doesn’t prevent you from having a cosmetic procedure, but there are safety and timing concerns to consider. Learn ...

Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While ...

Sun Pharma announced its partnership with music icon and ILUMYA® (tildrakizumab-asmn) patient, Art Garfunkel, as he shares ...

Investigators compared outcomes among patients with psoriasis undergoing apremilast treatment with genital involvement versus those without genital involvement.

Fact checked by Nick Blackmer Meet the Expert Marisa Garshick, MD, is a board-certified dermatologist and clinical assistant ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...